These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1929822)

  • 21. Tumour kinetics in breast cancer.
    Winters Z; Mohube P; Gray C; Wright C; Teare J; Lange M; Mannell A; Myburgh JA
    S Afr J Surg; 1994 Dec; 32(4):135-40. PubMed ID: 7597509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
    Thor AD; Liu S; Moore DH; Edgerton SM
    J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flow cytometry and cytomorphology in primary resectable breast cancer.
    Bedrossian CW; Raber M; Barlogie B
    Anal Quant Cytol; 1981 Jun; 3(2):112-6. PubMed ID: 6266303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.
    Stål O; Carstensen J; Hatschek T; Nordenskjöld B
    Br J Cancer; 1992 Oct; 66(4):706-11. PubMed ID: 1419611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
    Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
    Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prognostic factors in breast cancer].
    Jonat W; Eidtmann H; Friedrichs K
    Gynakologe; 1994 Feb; 27(1):37-44. PubMed ID: 8168736
    [No Abstract]   [Full Text] [Related]  

  • 27. DNA ploidy of human breast cancer.
    Del Bino G; Silvestrini R; Zucconi MR; Marchese G; Valentinis B; Di Fronzo G; Andreola S
    Anal Cell Pathol; 1989 Aug; 1(4):215-23. PubMed ID: 2487046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression.
    Schneeweiss A; Sinn HP; Ehemann V; Khbeis T; Neben K; Krause U; Ho AD; Bastert G; Krämer A
    Int J Cancer; 2003 Nov; 107(3):346-52. PubMed ID: 14506732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo effect induced by interferon beta on steroid receptor status, cell kinetics and DNA ploidy in operable breast cancer patients.
    Di Martino L; Demontis B; Saccani Iotti G; Murenu G
    Anticancer Res; 1995; 15(2):537-41. PubMed ID: 7763036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade.
    Weidner N; Moore DH; Ljung BM; Waldman FM; Goodson WH; Mayall B; Chew K; Smith HS
    Am J Surg Pathol; 1993 Oct; 17(10):987-94. PubMed ID: 8372950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
    Keshgegian AA; Cnaan A
    Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of the Tritiated Thymidine Labeling Index in breast cancers.
    Araki K; Kimura M; Sakamoto K; Nishimura R; Akagi M
    Jpn J Surg; 1985 Mar; 15(2):144-9. PubMed ID: 4010096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling.
    Meyer JS; Nauert J; Koehm S; Hughes J
    J Histochem Cytochem; 1989 Sep; 37(9):1449-54. PubMed ID: 2768814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry.
    Helin HJ; Helle MJ; Kallioniemi OP; Isola JJ
    Cancer; 1989 May; 63(9):1761-7. PubMed ID: 2649227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    Oncology; 2002; 63(1):48-55. PubMed ID: 12187071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
    Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
    Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of human breast cancer cell kinetics measured by flow cytometry and thymidine labeling.
    McDivitt RW; Stone KR; Craig RB; Meyer JS
    Lab Invest; 1985 Mar; 52(3):287-91. PubMed ID: 2983150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
    Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
    Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study.
    Meyer JS; Prey MU; Babcock DS; McDivitt RW
    Lab Invest; 1986 Jan; 54(1):41-51. PubMed ID: 3941541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens.
    Dressler LG; Seamer LC; Owens MA; Clark GM; McGuire WL
    Cancer; 1988 Feb; 61(3):420-7. PubMed ID: 3338012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.